Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

A month has gone by since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS) . Shares have added about 7.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Apellis Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been ...

It has been about a month since the last earnings report for Krystal Biotech, Inc. (KRYS) . Shares have lost about 3.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Krystal Biotech due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving ...

Group 1 - Myriad Genetics (MYGN) shares have increased by approximately 23.9% over the past month, outperforming the S&P 500 [1] - Recent estimates for Myriad have trended downward, with a consensus estimate shift of -5.56% [2] - Myriad has a Growth Score of A, a Momentum Score of F, and a Value Score of C, resulting in an aggregate VGM Score of C [3] Group 2 - The overall outlook for Myriad indicates a downward shift in estimates, with a Zacks Rank of 3 (Hold), suggesting an in-line return expected in the coming months [4] - Myriad is part of the Zacks Medical - Biomedical and Genetics industry, where GSK has gained 9.8% over the past month [5] - GSK reported revenues of $9.46 billion for the last quarter, reflecting a year-over-year increase of +1.4% [5]

CG Oncology, Inc. (CGON) shares ended the last trading session 25% higher at $27.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.3% loss over the past four weeks.CG Oncology’s shares jumped 25% on Monday after the company unveiled exceptionally durable best-in-disease phase III data for its bladder cancer candidate, cretostimogene grenadenorepvec, at the American Urological Association meeting. In the BOND-0 ...